Loading resource…

KDIGO
The document presents recommendations and practice points for medication management in CKD, with a focused update organized around major drug classes. It includes evidence reviews and discussion of clinical outcomes, including finerenone use in people with and without diabetes. The guideline also describes its development methods, evidence certainty, and recommendation grading. The document is marked as a draft for public review and feedback and states that it should not be used for other purposes.
No account needed
Answers use this document only.
Resources from the same specialty and type. Curated links will replace these when added.
Documents that extend or complement this resource.

Integrated CKD Management Guidelines for Uganda
Same clinical topic · Nephrology

KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD)
Same clinical topic · Nephrology

KDIGO 2026 CLINICAL PRACTICE GUIDELINE FOR DIABETES AND CHAPTER 1, CHAPTER 2, & CHAPTER 4 UPDATE DRAFT
Same clinical topic · Nephrology

KDIGO 2025 Clinical Practice Guideline for Anemia in Chronic Kidney Disease (CKD)
Same clinical topic · Nephrology

KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD)
Same clinical topic · Nephrology

DIABETES MANAGEMENT IN CHRONIC KIDNEY DISEASE: SYNOPSIS OF THE KDIGO 2022 CLINICAL PRACTICE GUIDELINE UPDATE
Same clinical topic · Nephrology

TREATMENT OF HYPERKALEMIA IN ADULTS
Same clinical topic · Nephrology

KDIGO-2024-CKD-Guideline
Same clinical topic · Nephrology

KDIGO 2023 CLINICAL PRACTICE GUIDELINE FOR THE MANAGEMENT OF LUPUS NEPHRITIS
Same clinical topic · Nephrology